TAK-778 enhances osteoblast differentiation of human bone marrow cells

✍ Scribed by Adalberto L. Rosa; Marcio M. Beloti

• Publisher: John Wiley and Sons
• Year: 2003
• Tongue: English
• Weight: 172 KB
• Volume: 89
• Category: Article
• ISSN: 0730-2312
• DOI: 10.1002/jcb.10582

✦ Synopsis

Abstract

TAK‐778 has been shown to induce bone growth in in vitro and in vivo models. However, there are no studies evaluating the effect of TAK‐778 on human cells. Thus, the aim of this study was to investigate osteogenesis induced by TAK‐778 on human bone marrow cells. Cells were cultured in 24‐well culture plates at a cell density of 2 × 10^4^ cells/well in culture medium containing TAK‐778 (10^−7^, 10^−6^, and 10^−5^ M, each) or vehicle. During the culture period, cells were incubated at 37°C in a humidified atmosphere of 5% CO~2~ and 95% air. For attachment evaluation, cells were cultured for 4 and 24 h. After 7, 14, and 21 days, cell proliferation, cell viability, total protein content, alkaline phosphatase (ALP) activity, and bone‐like formation were evaluated. Data were compared by ANOVA and Duncan's multiple range test. TAK‐778 did not affect cell attachment and viability. Cell number was reduced by TAK‐778 in all time period evaluated in a dose‐dependent way. The effect of TAK‐778 on total protein content, ALP activity and bone‐like formation was a dose‐dependent increase. The present results suggest that initial cell events such as cell attachment are not affected by TAK‐778 while events that indicate osteoblast differentiation including reduced cell proliferation, and increased both ALP activity and bone‐like formation are enhanced by TAK‐778 in a time and dose‐dependent way. It means that TAK‐778 could be a useful drug to enhance new bone formation in clinical situations that require rapid restoration of physiologic function, such as orthopedic and maxillofacial surgery. © 2003 Wiley‐Liss, Inc.